Background. NG Monomethyl-L-arginine (L-NMMA), a specific inhibitor of nitric oxide synthesis, was used to determine the effects of inhibition of nitric oxide synthesis in the human coronary circulation.
hndothelium-derived relaxing factor (EDRF) was first demonstrated more than a decade ago by Furchgott and Zawadzki.' Although the identity of EDRF remains uncertain, it now seems likely that nitric oxide or a closely related compound represents one type of EDRF, because both nitric oxide and EDRF display similar biological and pharmacological properties2-4 and nitric oxide is released in sufficient quantities to explain the biological actions of EDRF. 2 Other studies have indicated that nitric oxide cannot account for all the actions of EDRF and that, depending on the species, the vascular bed studie , and the mechanism of activation, there may be more than one type of EDRF. [5] [6] [7] [8] Nitric oxide is synthesized by endothelial cells from L-arginine.9 NG-monomethyl-L-arginine (L-NMMA) has been shown to inhibit its formation in a concentration-dependent and stereospecific manner.'0 L-NMMA inhibits endothelium-dependent relaxation,' and it increases the basal tone and attenuates the acetylcholineinduced relaxation in rings of rabbit aorta" and guinea pig pulmonary artery.'2 It increases the coronary vasSee p 325 cular resistance and attenuates the acetylcholine-induced vasodilatation in the Langendorff-perfused rabbit heart preparation. '3 In the resting conscious dog, Chu et al '4 showed that the systemic infusion of L-NMMA, in doses sufficient to significantly increase systemic blood pressure, caused a small decrease in epicardial coronary artery diameter together with a small reduction in coronary blood flow, indicating a rise in coronary vascular resistance resulting from an increase in resistive vessel tone. In contrast, Woodman and Dusting's showed that in the anesthetized dog, inhibition of nitric oxide synthesis with the inhibitor N-nitro-L-arginine caused a decrease in epicardial coronary artery diameter without affecting coronary blood flow or coronary vascular resistance despite a significant rise in arterial blood pressure. Vallance et a116 showed that in the human forearm, infusion of L-NMMA into the brachial artery substantially reduced basal blood flow and markedly inhibited the acetylcholine-induced increase in blood flow. The effects of L-NMMA were reversed by the infusion of L-arginine but not D-arginine, indicating stereospecific inhibition of nitric oxide synthesis, and also by nitroglycerin. 16 The purpose of this study was to determine the effects of inhibition of nitric oxide production by L-NMMA in the human coronary circulation. The effects of an intracoronary infusion of L-NMMA on epicardial coronary artery basal vasomotor tone and on coronary venous oxygen saturation, an index of coronary blood flow, were investigated. In addition, the effects of L-NMMA on the coronary vascular responses to acetylcholine (an endothelium-dependent vasodilator) and sodium nitroprusside (an endothelium-independent vasodilator) were examined. Methods The study was approved by the Research Ethics Committee of Hammersmith Hospital. All patients gave informed and written consent.
Patients
Twelve patients (four men and eight women; mean age, 52±2 years; range, 44 to 61 years) referred for cardiac catheterization were studied. All were undergoing investigation for assessment of atypical chest pain and had exercise tests that were negative at high work loads. All were in sinus rhythm and had normal ECGs. Patients with hyperlipidemia, hypertension, and diabetes mellitus were excluded. One patient smoked but refrained from doing so for 48 hours before the study. No patient with other significant risk factors was studied, so as to minimize the possibility that the patients had early coronary atherosclerosis. All patients had entirely smooth coronary arteriograms, and the left ventricular angiograms were normal. In seven patients, a noncardiovascular diagnosis was subsequently established; three had musculoskeletal chest pain, one gastritis, one gastric ulcer, one esophageal reflux, and one hyperventilation syndrome; in five patients, symptoms resolved spontaneously. All drug therapy was discontinued at least 48 hours before the studies.
Since L-NMMA (Novabiochem, Nottingham, UK) had not previously been infused into the human coronary circulation and animal studies had shown a variable response of the coronary vascular resistance and coronary blood flow to L-NMMA,13-5,17 we performed an initial dose-ranging study to confirm that L-NMMA would not induce ischemia (protocol A). Vallance et a116 had shown that in the human forearm, the intra-arterial infusion of L-NMMA caused a dosedependent reduction in forearm blood flow of up to 50% with doses of L-NMMA of up to 4 ,umol/min. The effects of L-NMMA were reversible with nitroglycerin. via the right femoral artery. On completion of the diagnostic procedure, the right coronary artery was reintubated with a 7F Judkins catheter (Cordis Corp), through which all infusions were given. A suitable radiographic projection was selected to obtain clearly defined arteriograms of the right coronary artery. The high-resolution 12.7-cm image intensifier (Optimus M200, Phillips) was not moved from this time on. Systemic blood pressure (right iliac artery), heart rate, and ECG were recorded continuously throughout the study.
The control infusion was 0.9% saline, and L-NMMA and sodium nitroprusside were dissolved in 0.9% saline. A control infusion of saline was given into the right coronary artery via the Judkins catheter, followed by incremental doses of L-NMMA (0.01, 0.1, 1.0, 2.0, and 5.0 umol/min, each for 3 minutes), followed by incremental doses of sodium nitroprusside (8, 16, 24, 32 , and 40 ,ug/min, each for 1 minute). An interval of 5 minutes was left between completion of the L-NMMA infusion and the infusion of sodium nitroprusside. All infusions were at the rate of 2 Index of left anterior descending coronary artery blood flow. If we make the following assumptions: 1) the great cardiac vein collects the majority of blood draining the left anterior descending coronary artery territory; 2) the predominant determinant of myocardial oxygen consumption is the heart rate-systolic blood pressure product; 3) there was no significant endocardial to epicardial redistribution of blood flow during the study; and 4) Proximal LAD acetylcholine before and after the L-NMMA infusion, followed by paired t tests at each dose with the Bonferroni correction for multiple comparisons. The responses of the proximal and distal coronary artery segments were analyzed separately, because previous studieS23 24,27,28have shown that there are segmental variations in the responsiveness of the epicardial coronary arteries to vasoactive stimuli. Linear regression analysis was used to correlate the responses of the artery segments to the L-NMMA infusion with the responses to the sodium nitroprusside infusion and to evaluate the relation between the segment diameters and the responses to the various agents. A value of P<0.05 was considered significant.
Results
The procedure was well tolerated by all patients. None of the patients experienced chest pain during the study, and the surface ECG did not change. There were no other side effects. lengths of the proximal and distal segments analyzed were 5.1±0.6 and 9.3±1.5 mm, respectively. The intracoronary infusion of L-NMMA had no effect on heart rate or arterial blood pressure ( There were no significant changes in heart rate, arterial blood pressure, or heart rate-systolic blood pressure product during the various infusions in these six patients (Table 3) . During the intracoronary infusion of acetylcholine at 100 nmol/min, dilatation of the distal segments of the left anterior descending coronary artery occurred in all patients (Fig 6) ; the mean percentage increase in diameter compared with saline control was 13.8±5.4%, P=0.049, and the response to acetylcholine was dose-dependent (Fig 7) . The responses of the proximal segments were more variable, with dilatation occurring in four patients and constriction in two. The mean percentage increase in diameter was 7.4±5.9%, P=0.27 (Fig 6) , which was significantly less than the response of the distal segments (P=0.041). Linear regression analysis of the responses of the 12 segments studied showed no significant correlation between the segment diameter and the response to acetylcholine either before or after the L-NMMA infusion. The oxygen saturation of the coronary venous blood rose from 36.5±3.5% to 59.2±2.8%, P<0.0001. There was no significant change in the product of heart rate and systolic blood pressure from 9924±1060 to 9993 ±985 beats per minute -mm Hg (Table 3 ). The changes in coronary venous oxygen saturation therefore represent a calculated increase in coronary blood flow of 57.0+7.1%, P=0.0005.
During the infusion of acetylcholine at 1, 10, and 100 nmol/min after the L-NMMA infusion, there was no significant change in either proximal (-3.9±4.0% at 100 nmol/min) or distal (-3.4±5.6% at 100 nmol/min) coronary artery diameter compared with the control saline infusion (Fig 7) . However, this represented a significant change from the effects of the acetylcholine infusions given before the L-NMMA infusion in both the proximal and distal coronary artery segments (P=0.023 and P=0.002, respectively, two-way repeatedmeasures ANOVA). There was an attenuation of the vasodilator action of acetylcholine and, in some patients, the unmasking of a vasoconstrictor effect (Figs 6  and 7) . In three patients, epicardial vessel constriction occurred in both the proximal and distal segments during the infusion of acetylcholine after L-NMMA; this dose had produced proximal segment dilatation in one and distal segment dilatation in all three of them before the L-NMMA infusion (Fig 6) . In contrast, the coronary venous oxygen saturation rose significantly, from 36.5 ±3.5% to 57.0±5.3%, P=0.0031 (Figs 6 and 7) during the acetylcholine infusion after L-NMMA, and the magnitude of this increase was not different from that induced by acetylcholine before L-NMMA. Again, there was no significant change in the heart rate-systolic blood pressure product (Table 3) , and the changes in coronary venous oxygen saturation therefore represent a calculated increase in coronary blood flow of 55.4±14.8%, P=0.013.
Discussion
This study demonstrates that, in the human coronary circulation, inhibition of nitric oxide synthesis with L-NMMA causes a small increase in basal tone of the distal segments of the epicardial coronary arteries together with a small fall in basal coronary blood flow. These data indicate a small tonic release of nitric oxide under basal conditions in the distal epicardial coronary arteries and in at least some of the resistive vessels. Sodium nitroprusside, a direct donor of nitric oxide,29 causes dilatation of both the proximal and distal epicardial coronary arterial segments together with an increase in coronary blood flow. Even at high intracoronary doses of sodium nitroprusside, just less than those sufficient to reduce systemic blood pressure, dilatation of the resistive vessels through the nitric oxide-dependent pathway causes only a moderate increase in coronary blood flow (68±15%). L-NMMA inhibits acetylcholine-induced coronary artery dilatation but does not affect acetylcholine-induced increases in coronary blood flow. L-NMMA, in intracoronary doses up to 25 ,mol/min, does not change heart rate or arterial blood pressure (Table 2) .
Since an inhibitor of nitric oxide synthesis had not previously been infused into the human coronary circulation, we elected initially to infuse very low doses of L-NMMA into the nondominant right coronary artery of the first two patients (protocol A). There were no adverse effects, and in one of these two patients, constriction of the distal right coronary artery was observed at the highest dose (5 ,umol/min caused by direct inhibition of nitric oxide synthesis. In this study, we avoided systemic hemodynamic changes by infusing all the agents directly into the coronary circulation, and the doses of L-NMMA and acetylcholine selected did not significantly change heart rate or systemic blood pressure (Tables 2 and 3) .
In previous studies, indirect evidence for the role of nitric oxide production in the human coronary circulation has been obtained with agents that are known to stimulate endothelial nitric oxide production (for example, acetylcholine,23 substance p,24 and serotonin25,30). Intracoronary infusion of each of these agents causes dilatation of normal epicardial coronary arteries in humans, and this effect has been shown to vary along the length of the epicardial vessel23-25,30 ; the effect at a given dose is more marked in the distal than in the proximal segments.
These reports,23-25,30 together with our data (Figs 3  and 4) , suggest a difference in behavior between the proximal and distal epicardial coronary artery segments in response to vasoactive agents. In our study, this difference may either result from a specific difference in basal nitric oxide production and responsiveness between different coronary artery segments or simply reflect a nonspecific reduction of responsiveness of the proximal and larger coronary artery segments to all vasoactive stimuli. In support of this latter view, a large study by Brown et a128 demonstrated an inverse relation between epicardial coronary artery responsiveness and segment diameter for every vasoactive agent, both constrictor and dilator, that they examined. They studied agents acting through both nitric oxide-related mechanisms (eg, sodium nitroprusside) and nitric oxide-independent mechanisms (eg, verapamil). Their findings28 indicate that the differences between proximal and distal vessel responsiveness that we observed may be nonspecific and not confined to the nitric oxide system.
In addition, in the distal epicardial coronary artery segments, we observed a significant inverse correlation between the magnitude of the vasoconstrictor response to the L-NMMA infusion and the vasodilator response to the sodium nitroprusside infusion (Fig 5) . The corresponding analysis was not performed for the proximal segments because of the lack of a significant change in proximal segment diameter during the L-NMMA infusion. We speculate that there is variation in basal endogenous nitric oxide activity in the distal coronary artery segments between individual patients. Thus, those patients with a large response to the L-NMMA infusion may have had a high basal nitric oxide activity and only a small incremental response to sodium nitroprusside, a donor of nitric oxide, because the nitric oxide pathway was already substantially activated. In addition, in these patients, the response to sodium nitroprusside may have been attenuated further by the development of tolerance, which recent experimental work has suggested may occur after prolonged activation of the nitric oxide pathway.31 In contrast, the patients with a low basal nitric oxide activity may have had a small response to the L-NMMA infusion but a large response to sodium nitroprusside (Fig 5) . Effect of L-NMMA on Coronary Resistive Vessels Myocardial work as assessed by the heart rate-systolic blood pressure product remained unchanged through-1 out the L-NMMA infusion, and according to the indirect Fick principle, coronary venous oxygen saturation can be used as an index of coronary blood flow. The coronary venous oxygen saturation decreased only slightly during the L-NMMA infusion (Figs 3 and 4) . These findings are compatible with a small decrease (5.7+1.9%) in coronary blood flow in response to the L-NMMA infusion, indicating a small increase in coronary resistance caused by a small increase in resistive vessel tone, and are consistent with the measurements reported in the chronically instrumented dog.14 However, our results contrast with those of Amezcua et al,13 who demonstrated that in the isolated and bufferperfused rabbit heart, L-NMMA (with a perfusate concentration of 30 to 100 gmol/L) caused a marked increase in coronary perfusion pressure of up to 120% above baseline, indicating a similar increase in coronary vascular resistance. This finding13 indicates that, in the buffer-perfused rabbit coronary circulation, there is a high basal effect of nitric oxide. Hemoglobin is an inhibitor of nitric oxide,32 so when the coronary circulation is perfused with whole blood, the effect of nitric oxide, which is released under basal conditions, would be expected to be substantially attenuated. When the coronary circulation is buffer-perfused, this mechanism of attenuation is removed; therefore, there might be a higher basal effect of nitric oxide under these conditions. Thus, addition of L-NMMA might be expected to cause a much greater relative increase in coronary vascular resistance in the buffer-perfused heart compared with the blood-perfused heart.
In the human forearm,'6 an estimated arterial concentration of L-NMMA similar to that used in our study reduced blood flow by 50% without any change in blood pressure. Thus, in humans, there appears to be considerable variability in response to L-NMMA at similar arterial concentrations between the coronary and forearm circulations. The reasons for this are uncertain but presumably reflect either increased tonic release of nitric oxide in the forearm resistive vessels or a different role for nitric oxide in the peripheral circulation compared with the coronary circulation.
Effect of L-NMMA on the Coronary Vascular Responses to Acetylcholine
The intracoronary infusion of acetylcholine has been reported previously to cause dose-dependent dilatation of the epicardial coronary arteries18,23,33 together with an increase in coronary venous oxygen saturation23 and coronary blood flow; these findings were confirmed in the present study (Figs 6 and 7) . L-NMMA inhibited the acetylcholine-induced epicardial coronary artery dilatation of the distal coronary artery segments ( Figs 6  and 7) ; this provides strong evidence that acetylcholine dilates the epicardial coronary arteries by the stimulation of nitric oxide synthesis. L-NMMA did not affect the acetylcholine-induced increase in coronary venous oxygen saturation, however ( Figs 6 and 7) ; this is consistent with the view that the vasodilator effect of acetylcholine on the resistive vessels is independent of nitric oxide synthesis.
Sodium nitroprusside in doses just less than those sufficient to cause a fall in systemic blood pressure induced a calculated increase in coronary blood flow of 68+15%. In contrast, acetylcholine has previously been shown by our group,23 in similar patients and using the same methods, to cause an increase in coronary blood flow of 167% at a dose of 1000 nmol/min. In the present study, however, the maximal dose of acetylcholine was 100 nmol/min; we did not use a dose of 1000 nmol/min, because it had been shown previously23 to induce constriction of normal epicardial arteries that had dilated at the lower dose of 100 nmol/min. Thus, the maximum vasodilator response of the resistive vessels to acetylcholine considerably exceeds that of the resistive vessels to sodium nitroprusside, and this provides further evidence that the vasodilator effect of acetylcholine on the resistive vessels is at least in part independent of nitric oxide. This conclusion is supported by the work of Although these reportsl'534,35 differ from our study, since we demonstrated that in the human coronary circulation L-NMMA had no effect on the acetylcholine-induced increase in coronary blood flow (Figs 6 and 7) , they indicate that acetylcholine dilates at least some coronary resistive vessels by a mechanism that cannot be completely inhibited by L-NMMA and hence is independent of nitric oxide synthesis.
The failure of L-NMMA to block acetylcholineinduced resistive vessel dilatation (Figs 6 and 7) has several possible explanations. The nitric oxide synthesis pathway in the resistive vessels compared with the epicardial arteries may be less sensitive or even completely insensitive to inhibition by L-NMMA. We consider that it is unlikely to be completely insensitive to inhibition by L-NMMA, because we demonstrated a significant reduction in coronary blood flow during the L-NMMA infusion, indicating at least some inhibition of nitric oxide synthesis in the resistive vessels. In addition, in other studies10,36 in which the dose-dependence of inhibition of the nitric oxide pathway has been assessed, concentrations of L-NMMA equivalent to the estimated arterial concentrations in our study (143 to 200 gmol/L) caused near-maximal inhibition of nitric oxide activity. It is possible that acetylcholine dilates the resistive vessels by increasing nitric oxide synthesis as a result of increasing the activity of another nitric oxide synthesis enzyme system that is insensitive to L-NMMA. A more likely explanation, however, is that the vasodilator effect of acetylcholine in the coronary resistive vessels is partly or completely independent of nitric oxide synthesis. It is unlikely to be a direct action on the vascular smooth muscle, because acetylcholine vasoconstricts in the absence of endothelium. Acetylcholine may act upon resistive vessels via the release of an intermediate vasodilator agent other than nitric oxide from the endothelium. The identity of such an agent remains speculative, but candidates might include adenosine37 and endothelium-derived hyperpolarizing factor.38
In our study, it is possible that if higher doses of L-NMMA had been given, we might have observed attenuation of the acetylcholine-induced increase in coronary blood flow. This would have indicated a different sensitivity of the resistive vessels to the effects of L-NMMA compared with the epicardial coronary arteries, because the acetylcholine-induced dilatation of the epicardial arteries was completely inhibited by L-NMMA (Fig 7) . We elected not to give higher intracoronary doses of L-NMMA because of a possible increase in systemic blood pressure and vasoconstriction in other vascular beds, in particular in the brain. 39, 40 Several studies18 23 Acetylcholine has variable effects in different vascular beds, vessel types, and species.5 '43 In the human forearm, L-NMMA infused into the brachial artery markedly attenuated the increase in forearm blood flow induced by acetylcholine,16 suggesting that increased nitric oxide synthesis may be the mechanism by which acetylcholine produces resistive vessel dilatation in the forearm. An alternative explanation is that the forearm conduit arteries, ie, the brachial artery and its major branches, may have become so constricted after the L-NMMA infusion that an increase in flow after resistive vessel dilatation with acetylcholine was prevented, but this seems unlikely, because resting flow was reduced by no more than 50%.
Limitations of the Study
It is possible that some of the patients had early coronary atherosclerosis, and this may affect endothelial function. To minimize this likelihood, only those patients who were free of significant cardiovascular risk factors were included, apart from one patient who smoked (Table 1 ), but this patient had a dilator response to acetylcholine. Early coronary atherosclerosis is associated with loss of the epicardial coronary artery dilator response to acetylcholine. [45] [46] [47] In our study, this response was preserved in the distal epicardial artery segments in all six patients and in the proximal segments in four of the six patients in whom it was assessed (Fig 6) . Therefore, it is likely that this group of patients was free from significant coronary atherosclerosis.
Coronary venous oximetry was selected in preference to intracoronary Doppler to measure coronary blood flow in this study because coronary arterial instrumentation may cause substantial endothelial denudation48 and nitric oxide is derived from the endothelium. The calculated changes in blood flow during the acetylcholine infusions in our study are consistent with those found by others using intracoronary Doppler.49 Coronary venous oxygen saturation is an indirect method that gives a continuous measurement of coronary blood flow but that may be affected by factors other than coronary blood flow, and we took care to control for these. In particular, possible interference from right atrial reflux into the coronary sinus was avoided by advancing the fiber-optic catheter tip far into the coro-nary sinus to the mouth of the great cardiac vein, and no patient developed heart block. Very recent preliminary evidence has suggested that an increase in nitric oxide activity may reduce myocardial contractility.50 It is not known whether a reduction in basal nitric oxide activity affects contractility in vivo. Chu et al17 measured left ventricular dP/dt in the chronically instrumented dog and found no change in this measurement, even when doses of L-NMMA sufficient to raise systemic blood pressure were given. In our study, heart rate and systolic blood pressure, the major determinants of cardiac work, were unchanged during the L-NMMA infusion; therefore, it is highly unlikely that there was an important change in cardiac metabolism.
Conclusions
Inhibition of nitric oxide synthesis in the coronary circulation of humans by the intracoronary infusion of L-NMMA decreases distal epicardial coronary artery basal diameter and basal coronary venous oxygen saturation, an index of coronary blood flow. These findings indicate that basal vasomotor tone in the epicardial coronary arteries and some coronary resistive vessels is at least in part maintained by the synthesis of nitric oxide. Acetylcholine-induced epicardial coronary artery dilatation is nitric oxide dependent, although at least some of its vasodilator effects on the resistive vessels appear to be independent of nitric oxide synthesis.
